October marks Breast Cancer Awareness Month, a time to spotlight the most common cancer among women. Early detection is ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after ...

Cancer vaccines train the immune system to combat foreign invaders like tumours, enhancing the body's ability to recognize ...

Gilead is withdrawing the accelerated approval of Trodelvy (sacituzumab govitecan-hziy) for metastatic urothelial cancer.

If prostate cancer spreads to other parts of the body, it can become deadly and commonly moves to bones, the lungs, lymph ...

Guatemala is setting new priorities for cancer control following a thorough review of its cancer care capacities and needs during an imPACT Review mission to the country. A team of nine international ...

An analysis of AYA cancer survivors in the US revealed “a substantial population of aging, long-term cancer survivors,” according to researchers.

Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the ...

Aged just 48, the 11-time Olympic gold medallist tragically has an incurable version of the disease which is expected to hit ...

Renal cell carcinoma is the most common form of it, and it can be difficult to treat as many symptoms don’t occur until it’s ...